全文获取类型
收费全文 | 2957篇 |
免费 | 260篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 27篇 |
儿科学 | 140篇 |
妇产科学 | 40篇 |
基础医学 | 411篇 |
口腔科学 | 110篇 |
临床医学 | 226篇 |
内科学 | 665篇 |
皮肤病学 | 43篇 |
神经病学 | 342篇 |
特种医学 | 206篇 |
外科学 | 386篇 |
综合类 | 91篇 |
一般理论 | 1篇 |
预防医学 | 187篇 |
眼科学 | 53篇 |
药学 | 129篇 |
中国医学 | 1篇 |
肿瘤学 | 172篇 |
出版年
2022年 | 20篇 |
2021年 | 43篇 |
2020年 | 36篇 |
2019年 | 40篇 |
2018年 | 71篇 |
2017年 | 33篇 |
2016年 | 52篇 |
2015年 | 56篇 |
2014年 | 76篇 |
2013年 | 111篇 |
2012年 | 134篇 |
2011年 | 125篇 |
2010年 | 116篇 |
2009年 | 91篇 |
2008年 | 118篇 |
2007年 | 132篇 |
2006年 | 125篇 |
2005年 | 112篇 |
2004年 | 115篇 |
2003年 | 104篇 |
2002年 | 103篇 |
2001年 | 66篇 |
2000年 | 75篇 |
1999年 | 73篇 |
1998年 | 87篇 |
1997年 | 62篇 |
1996年 | 61篇 |
1995年 | 55篇 |
1994年 | 42篇 |
1993年 | 46篇 |
1992年 | 46篇 |
1991年 | 54篇 |
1990年 | 46篇 |
1989年 | 51篇 |
1988年 | 57篇 |
1987年 | 48篇 |
1986年 | 51篇 |
1985年 | 72篇 |
1984年 | 44篇 |
1983年 | 27篇 |
1982年 | 26篇 |
1981年 | 25篇 |
1980年 | 19篇 |
1979年 | 30篇 |
1977年 | 25篇 |
1976年 | 29篇 |
1975年 | 17篇 |
1974年 | 16篇 |
1973年 | 22篇 |
1972年 | 16篇 |
排序方式: 共有3230条查询结果,搜索用时 31 毫秒
91.
92.
Prolactin-releasing peptide and its homolog RFRP-1 act in hypothalamus but not in anterior pituitary gland to stimulate stress hormone secretion 总被引:3,自引:0,他引:3
The RF-amide peptides (RFRPs), including prolactin (PRL)-releasing peptide-31 (PrRP-31) and RFRP-1, have been reported to
stimulate stress hormone secretion by either direct pituitary or indirect hypothalamic actions. We examined the possible direct
effects of these peptides on PRL and adrenocorticotropin (adrenocorticotropic hormone [ACTH]) release from dispersed anterior
pituitary cells in culture and on PRL and ACTH secretion following intracerebroventricular (icv) administration in vivo. Neither
peptide significantly altered PRL or ACTH release from cultured pituitary cells (male rat donors). Central administration
of 1.0 and 3.0 nmol of PrRP-31, but only the higher dose of RFRP-1, significantly elevated serum corticosterone levels in
conscious male rats. The effect of PrRP-31 was not blocked by pretreatment (iv) with the corticotropin-releasing hormone (CRH)
antagonist, α-helical CRH 9–41; however, pretreatment of the animals (iv) with an antiserum to CRH significantly lowered the
hypothalamic-pituitary-adrenal axis response to central administration of PrRP-31. On the other hand, the release of PRL was
significantly elevated by 3.0 nmol of RFRP-1, but not PrRP-31, in similarly treated, conscious male rats. Pretreatment with
the catecholamine synthesis inhibitor, α-methyl-para-tyrosine, prevented the stimulation of PRL secretion observed following
central administration of RFRP-1. RFRP-1 similarly did not alter PRL secretion in rats pretreated with the dopamine, D2 receptor blocker, domperidone. These results suggest that the RF-amide peptides are not true neuroendocrine regulators of
stress hormone secretion in the rat but, instead, act centrally to alter the release of neuroendocrine factors that do act
in the pituitary gland to control PRL and ACTH release. In the case of RFRP-1, stimulation of PRL secretion is potentially
owing to an action of the peptide to inhibit dopamine release into the median eminence. The corticosterone secretion observed
following central administration of PrRP-31 does not appear, based on our current results, to be solely owing to an action
of the peptide on CRH-producing neurons but, instead, may be a result of the ability of PrRP-31 to increase as well the exposure
of the corticotrophs in vivo to other ACTH secretagogues, such as oxytocin or vasopressin. 相似文献
93.
94.
Odaburhine E. Osime Joseph U. Ese-Onakewhor Samson O. Kolade 《Saudi medical journal》2015,36(2):200-203
Objectives:
To report on the changes in fibrinolytic activity in human immunodeficiency virus (HIV) infected pregnant women who are undergoing highly active antiretroviral therapy (HAART).Methods:
Blood was collected from 50 HIV positive women on HAART (test subjects), and 50 HIV positive women not on HAART (controls). These women were attending the prevention of mother to child clinic (PMTCT) of the University of Benin Teaching Hospital, Benin City, Nigeria from January to June 2014. Standard manual techniques were used to estimate plasma fibrinogen concentration (PFC), euglobulin lysis time (ELT), packed cell volume (PCV), and plasma viscosity (PV).Results:
The mean ± standard error of mean (SEM) of PFC was 4.02±0.13g/l and ELT from the test subjects was 378±15 mins was significantly higher (p<0.05) compared with the control subjects (PFC 3.46±0.12g/l and ELT 267±9.0mins). The PCV or hematocrit values in the test subject was 29.1±0.38%, which was significantly lower (p<0.05) compared with the control subject (31.3±0.43%). The PV in the test subject was 1.76±0.02 mPa/s, while the control subjects was higher (1.73±0.02 mPa/s). This increase was not statistically significant (p>0.05). There were differences in the various parameters investigated when the various trimesters were compared. These differences did not, however, follow a particular pattern.Conclusion:
Highly active antiretroviral therapy can cause changes in fibrinolytic activity that may predispose pregnant women to hyperfibrinogenemia and anemia.During pregnancy the physiology of a woman is temporary changed to accommodate the newly developing fetus.1 Conception occurs during ovulation, which is approximately on the fourteenth day of a regular menstrual cycle. In conception, the ovum is fertilized in the fallopian tube and becomes a zygote, which is then carried into the uterus. There are changes in the coagulation and fibrinolytic system during pregnancy and knowledge of these physiological changes characterized by hemodilution, changes in the concentration of one or more plasma protein fractions, and reduced fibrinolytic activity is necessary to manage 2 of the more serious problems in pregnancy; namely hemorrhage and thrombo-embolic diseases.2 Increased levels of plasma proteins and reduced fibrinolytic activity have been reported in pregnancy,3 while prolonged euglobulin lysis time (ELT) and increased levels of fibrinogen have also been observed in pregnancy.4 While numerous studies have examined optimal methods for prevention of mother to child transmission of human immunodeficiency virus (HIV) and subsequent response to HAART,5 as well as the impact of pregnancy on outcomes of HIV in the pre-HAART era,6 little is known of the impact of pregnancy on response to HAART in Africa. There are several biologically plausible mechanisms that might alter efficacy of several antiretroviral agents including changes in enzyme activity and beta-estradiol levels, pregnancy-related changes in blood volume and body mass index, and factors which may compromise adherence to HAART ante and post-partum, such as nausea/vomiting, labor-associated morbidity, or responsibility for a new infant.7 Human immunodeficiency virus infected patients have been reported to be at risk of cardiovascular diseases, (CVD) mostly due to the use of antiretroviral agents.8,9 Protease inhibitors have been mostly implicated.10 All these are also connected to fat redistribution dyslipidemia and insulin resistance observed in HIV patients;11,12 thus, this study aims to report on the changes in fibrinolytic activity in HIV infected pregnant women who are undergoing HAART. 相似文献95.
Ether lipids (EL) and hyperthermia have been shown to possess a relatively selective cytotoxicity to leukemic cells. In this study, the combined effects of EL (ET-18-OCH3, ET-16-NHCOCH3, or BM 41.440) and hyperthermia on the growth of hematopoietic progenitors, myeloid leukemic cell lines, and leukemic cells obtained from patients with acute myeloid leukemia (AML) were examined to determine if this combination resulted in a greater selective killing of leukemic cells than that achieved by either EL or heat alone. When the cells were treated simultaneously with EL (50 micrograms/mL) and hyperthermia (42 degrees C) for one hour, the killing of leukemic cell line cells was enhanced considerably. Among the three EL, however, the combination of ET-18-OCH3 and heat seemed to be the most cytotoxic to leukemic cell line cells with no effect on the growth of hematopoietic progenitors. An increase in the duration of treatment with ET-18-OCH3 to four hours with heat added during the last hour resulted in a further reduction of leukemic cell line cells while sparing 50% of hematopoietic progenitors after cryopreservation. The combined treatment with ET-18-OCH3 and heat also inhibited the growth of leukemic progenitors obtained from AML patients by 97% to 100%. These data indicate that the combined treatment with EL and hyperthermia might offer an efficient means to eliminate myeloid leukemic cells in vitro. 相似文献
96.
Elevated numbers of primitive Philadelphia chromosome-positive (Ph+) progenitors, including long-term culture-initiating cells (LTC-IC) as well as colony-forming cells (CFC), have been previously described in the blood of patients with chronic myeloid leukemia (CML) in chronic phase with high white blood cell counts. In the present study, which focused primarily on an analysis of circulating progenitors present in such patients at diagnosis, we discovered the frequent and occasionally exclusive presence of circulating normal (Ph-) LTC-IC, often at levels above those seen for LTC-IC in the blood of normal individuals. The presence of detectable numbers of circulating Ph- LTC-IC was independent of the fact that the same peripheral blood samples also contained elevated numbers of predominantly or exclusively Ph+ CFC. Interestingly, both the Ph+ and Ph- LTC-IC in these samples were CD34+CD71- and variably CD38- and Thy-1+, as previously documented for LTC-IC in normal marrow. Thus, neither CD38 nor Thy-1 expression was useful for discriminating between Ph+ and Ph- LTC-IC in mixed populations. Nevertheless, an association of these phenotypes with LTC- IC function did allow highly enriched (> 5% pure) suspensions of either Ph+ or Ph- LTC-IC to be obtained from selected samples of CML blood in which the initial LTC-IC population was either predominantly Ph+ or Ph- , respectively. These findings suggest that the mechanisms causing mobilization of leukemic stem cells in untreated CML patients may affect their normal counterparts. They also indicate a possible new source of autologous cells for the support of intensive therapy of CML patients. Finally, they provide a method for obtaining the most highly purified populations of Ph+ LTC-IC described to date. This method should be useful for further analyses of the molecular activities of these very primitive neoplastic cells. 相似文献
97.
Gahrton G Svensson H Cavo M Apperly J Bacigalupo A Björkstrand B Bladé J Cornelissen J de Laurenzi A Facon T Ljungman P Michallet M Niederwieser D Powles R Reiffers J Russell NH Samson D Schaefer UW Schattenberg A Tura S Verdonck LF Vernant JP Willemze R Volin L;European Group for Blood Marrow Transplantation 《British journal of haematology》2001,113(1):209-216
Out of 690 allogeneic matched sibling donor transplants for multiple myeloma reported to the European Group for Blood and Marrow Transplantation (EBMT) registry, 334 were performed during the period 1983-93 (all with bone marrow) and 356 during 1994-98 [223 with bone marrow and 133 with peripheral blood stem cells (PBSCs)]. The median overall survival was 10 months for patients transplanted during the earlier time period and 50 months for patients transplanted with hone marrow during the later period. The use of PBSCs was associated with earlier engraftment but no significant survival benefit compared to bone marrow transplants during the same time period. The improvement in survival since 1994 with the result of a significant reduction in transplant-related mortality, which was 38%, 21% and 25% at 6 months and 46%, 30% and 37% at 2 years during the earlier period, and the later period with bone marrow and PBSCs respectively. Reasons for the reduced transplant-related mortality appeared to be fewer deaths owing to bacterial and fungal infections and interstitial pneumonitis, in turn a result of earlier transplantation and less prior chemotherapy. Better supportive treatment and more frequent use of cytokines may also play a role. The improvement in survival was not directly related to the increased use of PBSCs. 相似文献
98.
Prevalence of Giant Cell Arteritis Relapse in Patients Treated With Glucocorticoids: A Meta‐Analysis
99.
100.